search
Back to results

Dose Finding Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis

Primary Purpose

Alpha Mannosidosis

Status
Unknown status
Phase
Phase 2
Locations
Denmark
Study Type
Interventional
Intervention
Lamazym
Sponsored by
Zymenex A/S
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Alpha Mannosidosis

Eligibility Criteria

5 Years - 21 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. The patient must have a confirmed diagnosis of alpha-Mannosidosis as defined by alpha-mannosidase activity < 10% of normal activity in blood leukocytes
  2. The patient must have an age at the time of screening ≥ 5 year and ≤ 21 years
  3. The patient must have physical ability to perform 6-minutes walk test (6MWT), 3 minute-stair climb test (3MSCT) and pulmonary lung function test (spirometry, body plethysmography).
  4. The patient must have the ability to mentally cooperate in the cognitive and motor function tests
  5. The patient must have the ability to hear and follow a request. Hearing aids can be worn.
  6. Patient or patient's legally authorized guardian(s) must provide signed, informed consent prior to performing any study-related activities (trial-related activities are any procedures that would not have been performed during normal management of the subject)
  7. The patient and his/her guardian(s) must have the ability to comply with the protocol

Exclusion Criteria:

  1. The patient cannot walk without support.
  2. Presence of known chromosomal abnormality and syndromes affecting psychomotor development, other than alpha-Mannosidosis
  3. History of bone marrow transplantation
  4. Presence of known clinically significant cardiovascular, hepatic, pulmonary or renal disease or other medical conditions that, in the opinion of the Investigator, would preclude participation in the trial
  5. Presence of an ECHO with abnormalities within half a year that, in the opinion of the Investigator, would preclude participation in the trial
  6. Any other medical condition or serious intercurrent illness, or extenuating circumstance that, in the opinion of the investigator, would preclude participation in the trial
  7. Pregnancy
  8. Psychosis within the last 3 months

Sites / Locations

  • Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Lamazym 25

Lamazym 50

Arm Description

25 U/kg

50 U/kg

Outcomes

Primary Outcome Measures

Reduction of Oligosaccharides in urine
Efficacy endpoint evaluation as change from baseline

Secondary Outcome Measures

Reduction of Oligosaccharides in serum
Efficacy endpoint evaluation as change from baseline
Reduction of Oligosaccharides in CSF
Efficacy endpoint evaluation as change from baseline
The distance walked in 6 minutes
Efficacy endpoint evaluation as change from baseline
The number of steps climbed in 3 minutes
Efficacy endpoint evaluation as change from baseline
Pulmonary Function
Efficacy endpoint evaluation as change from baseline
Adverse events
Safety endpoint assessed weekly throughout the trial
Development of clinically significant changes in vital signs and change in physical examination
Safety endpoint assessed weekly throughout the trial
Development of clinically significant changes in the clinical laboratory parameters (hematology, biochemistry and urinalysis)
Safety endpoint assessed every 4th week throughout the trial
Development of rhLAMAN antibodies and neutralizing/inhibitory antibodies
Safety endpoint assessed every other week throughout the trial

Full Information

First Posted
January 25, 2011
Last Updated
September 25, 2012
Sponsor
Zymenex A/S
Collaborators
European Commission
search

1. Study Identification

Unique Protocol Identification Number
NCT01285700
Brief Title
Dose Finding Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis
Official Title
A Single Center, Randomized, Open-label, Multiple-dose Study of the Efficacy and Long-term Safety of rhLAMAN (Recombinant Human Alpha-mannosidase or Lamazym) for the Treatment of Patients With Alpha-mannosidosis.
Study Type
Interventional

2. Study Status

Record Verification Date
September 2012
Overall Recruitment Status
Unknown status
Study Start Date
January 2011 (undefined)
Primary Completion Date
January 2012 (Actual)
Study Completion Date
November 2012 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Zymenex A/S
Collaborators
European Commission

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a single-center, open-label, multiple-dose study of the efficacy and long-term safety of Lamazym for the treatment of patients with alpha-mannosidosis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alpha Mannosidosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Lamazym 25
Arm Type
Active Comparator
Arm Description
25 U/kg
Arm Title
Lamazym 50
Arm Type
Active Comparator
Arm Description
50 U/kg
Intervention Type
Drug
Intervention Name(s)
Lamazym
Other Intervention Name(s)
rhLAMAN
Intervention Description
ERT, infusion weekly
Primary Outcome Measure Information:
Title
Reduction of Oligosaccharides in urine
Description
Efficacy endpoint evaluation as change from baseline
Time Frame
3 months (interim evaluation) + 6 months
Secondary Outcome Measure Information:
Title
Reduction of Oligosaccharides in serum
Description
Efficacy endpoint evaluation as change from baseline
Time Frame
3 months (interim evaluation) + 6 months
Title
Reduction of Oligosaccharides in CSF
Description
Efficacy endpoint evaluation as change from baseline
Time Frame
3 months (interim evaluation) + 6 months
Title
The distance walked in 6 minutes
Description
Efficacy endpoint evaluation as change from baseline
Time Frame
3 months (interim evaluation) + 6 months
Title
The number of steps climbed in 3 minutes
Description
Efficacy endpoint evaluation as change from baseline
Time Frame
3 months (interim evaluation) + 6 months
Title
Pulmonary Function
Description
Efficacy endpoint evaluation as change from baseline
Time Frame
3 months (interim evaluation) + 6 months
Title
Adverse events
Description
Safety endpoint assessed weekly throughout the trial
Time Frame
1 week
Title
Development of clinically significant changes in vital signs and change in physical examination
Description
Safety endpoint assessed weekly throughout the trial
Time Frame
1 week
Title
Development of clinically significant changes in the clinical laboratory parameters (hematology, biochemistry and urinalysis)
Description
Safety endpoint assessed every 4th week throughout the trial
Time Frame
4 weeks
Title
Development of rhLAMAN antibodies and neutralizing/inhibitory antibodies
Description
Safety endpoint assessed every other week throughout the trial
Time Frame
2 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: The patient must have a confirmed diagnosis of alpha-Mannosidosis as defined by alpha-mannosidase activity < 10% of normal activity in blood leukocytes The patient must have an age at the time of screening ≥ 5 year and ≤ 21 years The patient must have physical ability to perform 6-minutes walk test (6MWT), 3 minute-stair climb test (3MSCT) and pulmonary lung function test (spirometry, body plethysmography). The patient must have the ability to mentally cooperate in the cognitive and motor function tests The patient must have the ability to hear and follow a request. Hearing aids can be worn. Patient or patient's legally authorized guardian(s) must provide signed, informed consent prior to performing any study-related activities (trial-related activities are any procedures that would not have been performed during normal management of the subject) The patient and his/her guardian(s) must have the ability to comply with the protocol Exclusion Criteria: The patient cannot walk without support. Presence of known chromosomal abnormality and syndromes affecting psychomotor development, other than alpha-Mannosidosis History of bone marrow transplantation Presence of known clinically significant cardiovascular, hepatic, pulmonary or renal disease or other medical conditions that, in the opinion of the Investigator, would preclude participation in the trial Presence of an ECHO with abnormalities within half a year that, in the opinion of the Investigator, would preclude participation in the trial Any other medical condition or serious intercurrent illness, or extenuating circumstance that, in the opinion of the investigator, would preclude participation in the trial Pregnancy Psychosis within the last 3 months
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Allan M. Lund, MD
Organizational Affiliation
Department of Clinical Genetics, Juliane Marie Centre, Region Hovedstaden, Copenhagen University hospital, Denmark
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jens Fogh
Organizational Affiliation
Zymenex A/S
Official's Role
Study Chair
Facility Information:
Facility Name
Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9
City
Copenhagen
ZIP/Postal Code
2100
Country
Denmark

12. IPD Sharing Statement

Learn more about this trial

Dose Finding Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis

We'll reach out to this number within 24 hrs